{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:39:43Z","timestamp":1788586783191,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cmi.2025.04.021","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:46:19Z","timestamp":1745678779000},"page":"1451-1457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Gram-positive multiresistant bacteria prosthetic joint infection: a narrative review on current and innovative strategies"],"prefix":"10.1016","volume":"31","author":[{"given":"Florent","family":"Valour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Miot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Batailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.04.021_bib1","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.arth.2018.05.042","article-title":"Are we winning or losing the battle with periprosthetic joint infection: Trends in periprosthetic joint infection and mortality risk for the medicare population","volume":"33","author":"Kurtz","year":"2018","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.04.021_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jinf.2020.12.010","article-title":"Epidemiology of complex bone and joint infections in France using a national registry: The CRIOAc network","volume":"82","author":"Lemaignen","year":"2021","journal-title":"J Infect"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2025.04.021_bib3","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/jac\/dku254","article-title":"Impact of bacterial biofilm on the treatment of prosthetic joint infections","volume":"69","author":"Jacqueline","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: Pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2025.04.021_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1302\/2058-5241.6.210008","article-title":"Management strategies for prosthetic joint infection: Long-term infection control rates, overall survival rates, functional and quality of life outcomes","volume":"6","author":"Karachalios","year":"2021","journal-title":"EFORT Open Rev"},{"key":"10.1016\/j.cmi.2025.04.021_bib6","series-title":"Antimicrobial resistance surveillance in Europe 2023-2021 data","year":"2023"},{"key":"10.1016\/j.cmi.2025.04.021_bib7","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3390\/antibiotics11091244","article-title":"Microbiological trends and antibiotic susceptibility patterns in patients with periprosthetic joint infection of the hip or knee over 6 years","volume":"11","author":"Fr\u00f6schen","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib8","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1186\/s12891-021-04689-5","article-title":"Different microbial and resistance patterns in primary total knee arthroplasty infections\u2014A report on 283 patients from Lithuania and Sweden","volume":"22","author":"Sebastian","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.cmi.2025.04.021_bib9","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.arth.2023.02.025","article-title":"Increased incidence of methicillin-resistant Staphylococcus aureus in knee and hip prosthetic joint infection","volume":"38","author":"Hays","year":"2023","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.04.021_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmi.2018.04.035","article-title":"Microbiologic epidemiology depending on time to occurrence of prosthetic joint infection: A prospective cohort study","volume":"25","author":"Triffault-Fillit","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.021_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/antibiotics12010040","article-title":"The clinical outcome of early periprosthetic joint infections caused by Staphylococcus epidermidis and managed by surgical debridement in an era of increasing resistance","volume":"12","author":"Shabana","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/jcm8050673","article-title":"The different microbial etiology of prosthetic joint infections according to route of acquisition and time after prosthesis implantation, including the role of multidrug-resistant organisms","volume":"8","author":"Benito","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.cmi.2025.04.021_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2018.08.012","article-title":"Staphylococcus aureus versus Staphylococcus epidermidis in periprosthetic joint infection-Outcome analysis of methicillin-resistant versus methicillin-susceptible strains","volume":"93","author":"Hischebeth","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cid\/cis746","article-title":"A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention","volume":"56","author":"Lora-Tamayo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/j.1469-0691.2010.03333.x","article-title":"Early prosthetic joint infection: Outcomes with debridement and implant retention followed by antibiotic therapy","volume":"17","author":"Cobo","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.021_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/BLO.0b013e3181123d4e","article-title":"Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections","volume":"461","author":"Salgado","year":"2007","journal-title":"Clin Orthop Relat Res"},{"issue":"6 Suppl","key":"10.1016\/j.cmi.2025.04.021_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.arth.2010.04.011","article-title":"Periprosthetic joint infection: The economic impact of methicillin-resistant infections","volume":"25","author":"Parvizi","year":"2010","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.04.021_bib18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/antibiotics12101499","article-title":"Incidence of rifampicin resistance in periprosthetic joint infection: A single-centre cohort study on 238 patients","volume":"12","author":"Lazarinis","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/antibiotics12111589","article-title":"Early staphylococcal periprosthetic joint infection (PJI) treated with debridement, antibiotics, and implant retention (DAIR): Inferior outcomes in patients with staphylococci resistant to rifampicin","volume":"12","author":"Eriksson","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107015","article-title":"Clinical outcomes of rifampicin combination therapy in implant-associated infections due to staphylococci and streptococci: A systematic review and meta-analysis","volume":"63","author":"Yusuf","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.021_bib21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/cid\/cix227","article-title":"The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: The results of a large multicenter study","volume":"64","author":"Lora-Tamayo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.arth.2016.09.017","article-title":"Periprosthetic joint infections caused by enterococci have poor outcomes","volume":"32","author":"Kheir","year":"2017","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.04.021_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: Key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.cmi.2025.04.021_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5194\/jbji-6-7-2020","article-title":"Clinical use of linezolid in periprosthetic joint infections\u2014A systematic review","volume":"6","author":"Theil","year":"2020","journal-title":"J Bone Jt Infect"},{"key":"10.1016\/j.cmi.2025.04.021_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40121-014-0032-z","article-title":"A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention","volume":"3","author":"Morata","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.04.021_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01644-16","article-title":"Activity of tedizolid in methicillin-resistant Staphylococcus epidermidis experimental foreign body-associated osteomyelitis","volume":"61","author":"Park","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib27","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1128\/AAC.01248-16","article-title":"Activity of tedizolid in methicillin-resistant Staphylococcus aureus experimental foreign body-associated osteomyelitis","volume":"60","author":"Park","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antibiotics10010053","article-title":"Long-term use of tedizolid in osteoarticular infections: Benefits among oxazolidinone drugs","volume":"10","author":"Benavent","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01282-23","article-title":"Safety and tolerability of tedizolid as oral treatment for bone and joint infections","volume":"11","author":"Miller","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.cmi.2025.04.021_bib30","doi-asserted-by":"crossref","first-page":"23425","DOI":"10.1038\/s41598-021-02709-x","article-title":"In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus","volume":"11","author":"Jacob","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.04.021_bib31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib32","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65","author":"Cojutti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: A randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jgar.2021.03.026","article-title":"Dalbavancin treatment for prosthetic joint infections in real-life: A national cohort study and literature review","volume":"25","author":"Matt","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.04.021_bib35","doi-asserted-by":"crossref","first-page":"106773","DOI":"10.1016\/j.ijantimicag.2023.106773","article-title":"A descriptive case series of the relationship between maintenance of conservative PK\/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections","volume":"61","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.021_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dks344","article-title":"Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and \u03b2-haemolytic streptococci collected from western European countries in 2011","volume":"68","author":"Morrissey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2018.05.010","article-title":"In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection","volume":"92","author":"Yan","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2018.03.008","article-title":"In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci","volume":"91","author":"Yan","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib39","first-page":"959","article-title":"Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: Narrative review and possible developments","volume":"13","author":"Lupia","year":"2023","journal-title":"Life (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2025.04.021_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of acute osteomyelitis with once-weekly oritavancin: A two-year, multicenter, retrospective study","volume":"7","author":"Van Hise","year":"2020","journal-title":"Drugs Real World Outcome"},{"key":"10.1016\/j.cmi.2025.04.021_bib41","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1128\/AAC.03600-14","article-title":"Ceftaroline-fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model","volume":"58","author":"Gatin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib42","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/jac\/dkae071","article-title":"Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: A CRIOGO multicentre retrospective study","volume":"79","author":"Tessier","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.amjms.2022.01.016","article-title":"Early clinical experience with delafloxacin: A case series","volume":"363","author":"Hornak","year":"2022","journal-title":"Am J Med Sci"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2025.04.021_bib45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014","volume":"21","author":"H\u00f8iby","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.021_bib46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkaa061","article-title":"Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: Promising in vitro profile of rifabutin","volume":"75","author":"Abad","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/AAC.01570-12","article-title":"Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"57","author":"Garrig\u00f3s","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/antibiotics14020139","article-title":"Could a reduced dose of 8 g of continuous infusion fosfomycin be considered as effective as and safer than a standard 16 g dose when combined with high-dose daptomycin in the treatment of Staphylococcal osteoarticular infections?","volume":"14","author":"Cojutti","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib49","doi-asserted-by":"crossref","first-page":"106321","DOI":"10.1016\/j.ijantimicag.2021.106321","article-title":"Antimicrobial activity of the new FabI inhibitor afabicin desphosphono against intraosteoblastic Staphylococcus aureus","volume":"57","author":"Dyon-Tafani","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.021_bib50","doi-asserted-by":"crossref","first-page":"102774","DOI":"10.1016\/j.otsr.2020.102774","article-title":"Methods and probability of success after early revision of prosthetic joint infections with debridement, antibiotics and implant retention","volume":"107","author":"Boyer","year":"2021","journal-title":"Orthop Traumatol Surg Res"},{"key":"10.1016\/j.cmi.2025.04.021_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib52","doi-asserted-by":"crossref","first-page":"896978","DOI":"10.3389\/fcimb.2022.896978","article-title":"Estimation of minimum biofilm eradication concentration (MBEC) on in vivo biofilm on orthopedic implants in a rodent femoral infection model","volume":"12","author":"Okae","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cmi.2025.04.021_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1302\/1358-992X.2024.19.083","article-title":"The burden of broad-spectrum antibiotic use in orthopaedic infection: Systemic antibiotic prescribing in the SOLARIO trial","volume":"106-B","author":"Dudareva","year":"2024","journal-title":"Orthop Proc"},{"key":"10.1016\/j.cmi.2025.04.021_bib54","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/antibiotics13080772","article-title":"Antimicrobial regimens in cement spacers for periprosthetic joint infections: A critical review","volume":"13","author":"Naoum","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/antibiotics13060524","article-title":"Effect of multiantibiotic-loaded bone cement on the treatment of periprosthetic joint infections of hip and knee arthroplasties-A single-center retrospective study","volume":"13","author":"Blersch","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/antibiotics12040752","article-title":"Local antibiotic delivery options in prosthetic joint infection","volume":"12","author":"Steadman","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib57","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.arth.2020.11.033","article-title":"Outcome of irrigation and debridement with topical antibiotics delivery for the management of periprosthetic joint infection occurring within 3 months since the primary total joint arthroplasty","volume":"36","author":"Mu","year":"2021","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.cmi.2025.04.021_bib58","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/healthcare12080843","article-title":"Debridement, antibiotic pearls, and retention of the implant (DAPRI) in the treatment of early periprosthetic knee joint infections: A literature review","volume":"12","author":"Vicenti","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.cmi.2025.04.021_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-0716-3523-0_14","article-title":"A review of phage therapy for bone and joint infections","volume":"2734","author":"Ferry","year":"2024","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2025.04.021_bib60","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02231-19","article-title":"Evaluation of the activity of a combination of three bacteriophages alone or in association with antibiotics on Staphylococcus aureus embedded in biofilm or internalized in osteoblasts","volume":"64","author":"Kolenda","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib61","doi-asserted-by":"crossref","first-page":"570572","DOI":"10.3389\/fmed.2020.570572","article-title":"Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection","volume":"7","author":"Ferry","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cmi.2025.04.021_bib62","doi-asserted-by":"crossref","first-page":"107372","DOI":"10.1016\/j.ijantimicag.2024.107372","article-title":"Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme","volume":"64","author":"Ferry","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.021_bib63","doi-asserted-by":"crossref","first-page":"550853","DOI":"10.3389\/fmed.2021.550853","article-title":"Arthroscopic \u201cdebridement and implant retention\u201d with local administration of exebacase (Lysin CF-301) followed by suppressive tedizolid as salvage therapy in elderly patients for relapsing multidrug-resistant S. epidermidis prosthetic knee infection","volume":"8","author":"Ferry","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.cmi.2025.04.021_bib64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2025.04.021_bib65","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","article-title":"Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections","volume":"43","author":"Curis","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.04.021_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00023-24","article-title":"Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular\/periprosthetic joint infections","volume":"68","author":"Cattaneo","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.021_bib67","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/cid\/cit488","article-title":"Challenging issues in tuberculosis in solid organ transplantation","volume":"57","author":"Horne","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab351","article-title":"Safety of tedizolid as suppressive antimicrobial therapy for patients with complex implant-associated bone and joint infection due to multidrug-resistant Gram-positive pathogens: Results from the TediSAT cohort study","volume":"8","author":"Ferry","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.021_bib69","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-024-04849-0","article-title":"Dalbavancin as suppressive therapy for implant-related infections: A case series with therapeutic drug monitoring and review of the literature","volume":"43","author":"Lafon-Desmurs","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:23:22Z","timestamp":1788225802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1198743X25001843"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.021","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Gram-positive multiresistant bacteria prosthetic joint infection: a narrative review on current and innovative strategies","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}